Drug General Information |
Drug ID |
D0ZW9L
|
Former ID |
DNC007138
|
Drug Name |
5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H13N3O
|
Canonical SMILES |
C1=CC=C(C=C1)C2=CC(=NC3=C2NC(=O)N3)C4=CC=CC=C4
|
InChI |
1S/C18H13N3O/c22-18-20-16-14(12-7-3-1-4-8-12)11-15(19-17(16)21-18)13-9-5-2-6-10-13/h1-11H,(H2,19,20,21,22)
|
InChIKey |
SHTZPAWLYJASHR-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A3 receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Sphingolipid signaling pathway
|
Neuroactive ligand-receptor interaction
|
Morphine addictionhsa04015:Rap1 signaling pathway
|
Calcium signaling pathway
|
Vascular smooth muscle contraction
|
Parkinson's disease
|
Alcoholism
|
NetPath Pathway
|
TCR Signaling Pathway
|
RANKL Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Reactome
|
Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation
|
G alpha (s) signalling events
|
Surfactant metabolismR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Nucleotide GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCR ligand binding
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
Monoamine Transport
|
NGF signalling via TRKA from the plasma membrane
|
GPCR downstream signaling
|
GPCRs, OtherWP80:Nucleotide GPCRs
|
GPCRs, Other
|
References |
REF 1 | J Med Chem. 2007 Feb 22;50(4):828-34.2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. |